Novartis’ remibrutinib delivered positive top-line Phase 3 results in relapsing multiple sclerosis, making it the second oral Bruton’s tyrosine kinase inhibitor to post favorable efficacy data in the ongoing regulatory competition. The readout positions the drug behind Roche’s fenebrutinib, as developers race to establish a first BTK inhibitor option in relapsing MS. Multiple BTK programs have faced difficulties in prior attempts, including efficacy or liver safety concerns, increasing the importance of the latest outcome. The Phase 3 signal also affects how clinicians and payers may prioritize early BTK use if confirmatory data remain favorable. The move intensifies the likelihood that the first BTK-in-MS launch will come from a narrow set of assets, with differentiation expected around long-term tolerability and biomarker-aligned response rates.